ZBH Stock Chart & Stats
CHF75.00
CHF0.00(0.00%)
At close: 4:00 PM EDT
CHF75.00
CHF0.00(0.00%)
Day’s Range― - ―
52-Week RangeCHF62.50 - CHF119.00
Previous CloseN/A
Volume2.00
Average Volume (3M)0.00
Market Cap
CHF13.55B
Enterprise ValueCHF23.91B
Total Cash (Recent Filing)CHF424.20M
Total Debt (Recent Filing)CHF7.47B
Price to Earnings (P/E)22.6
Beta0.22
Next Earnings
Aug 04, 2026EPS Estimate
1.61Next Dividend Ex-DateN/A
Dividend Yield0.94%
Share Statistics
EPS (TTM)3.87
Shares Outstanding193,462,480
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-1.26
Price to Book (P/B)1.40
Price to Sales (P/S)2.16
P/FCF Ratio12.09
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF78.44Price Target Upside4.58% Upside
Rating ConsensusHold
Number of Analyst Covering16
EPS Forecast (FY)6.82
Revenue Forecast (FY)CHF6.87B
Bulls Say, Bears Say
Bulls Say
High Gross And EBITDA MarginsSustained high gross and EBITDA margins reflect durable cost structure and pricing power in orthopedic implants and consumables. These margins provide a persistent earnings buffer to fund R&D, robotics investment and share repurchases while absorbing modest pricing erosion over the next several quarters.
Robust Free Cash Flow GenerationConsistent positive free cash flow at a multibillion-dollar run rate underpins capital allocation flexibility: supports buybacks, deleveraging or robotics investment. Strong cash conversion reduces reliance on external funding and sustains strategic initiatives through 2–6 months of execution risk.
Technology & M&A MomentumAcceleration in robotics, digital tools and Paragon 28 contribution indicates structural growth drivers that boost surgeon stickiness and recurring procedure-related revenue. Successful M&A integration and product adoption support higher long-term revenue mix and differentiation versus peers.
Bears Say
Compressed Net Margin And Declining ROEEroding net margins and a falling ROE signal declining bottom-line efficiency despite healthy operating margins. Lower returns on equity constrain reinvestment capacity and may limit long-term EPS leverage, making earnings more sensitive to pricing and interest cost pressures.
Commercial Transformation & Legacy Product HeadwindsA multi-year go-to-market overhaul and legacy knee phase-outs create durable execution risk: account losses and productivity dips can depress procedure volumes and disrupt surgeon relationships, slowing organic growth and extending the timeline to realize salesforce efficiency gains.
Higher Interest Expense From Acquisition DebtElevated interest costs tied to M&A financing increase fixed overhead and reduce margin flexibility. Persistent higher nonoperating expense limits net income resilience to cyclical downturns and constrains cash available for reinvestment or accelerated deleveraging.
ZBH FAQ
What was Zimmer Biomet Holdings’s price range in the past 12 months?
Zimmer Biomet Holdings lowest stock price was CHF62.50 and its highest was CHF119.00 in the past 12 months.
What is Zimmer Biomet Holdings’s market cap?
Zimmer Biomet Holdings’s market cap is CHF13.55B.
When is Zimmer Biomet Holdings’s upcoming earnings report date?
Zimmer Biomet Holdings’s upcoming earnings report date is Aug 04, 2026 which is in 30 days.
How were Zimmer Biomet Holdings’s earnings last quarter?
Zimmer Biomet Holdings released its earnings results on Apr 28, 2026. The company reported CHF1.674 earnings per share for the quarter, beating the consensus estimate of CHF1.494 by CHF0.18.
Is Zimmer Biomet Holdings overvalued?
According to Wall Street analysts Zimmer Biomet Holdings’s price is currently Undervalued.
Does Zimmer Biomet Holdings pay dividends?
Zimmer Biomet Holdings pays a Quarterly dividend of CHF0.194 which represents an annual dividend yield of 0.94%. See more information on Zimmer Biomet Holdings dividends here
What is Zimmer Biomet Holdings’s EPS estimate?
Zimmer Biomet Holdings’s EPS estimate is 1.61.
How many shares outstanding does Zimmer Biomet Holdings have?
Zimmer Biomet Holdings has 193,462,480 shares outstanding.
What happened to Zimmer Biomet Holdings’s price movement after its last earnings report?
Zimmer Biomet Holdings reported an EPS of CHF1.674 in its last earnings report, beating expectations of CHF1.494. Following the earnings report the stock price went down -4.966%.
Which hedge fund is a major shareholder of Zimmer Biomet Holdings?
Currently, no hedge funds are holding shares in CH:ZBH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zimmer Biomet Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
CHF78.44 (4.58% Upside)
CHF78.44 (4.58% Upside)
Blogger Sentiment
Bullish
CH:ZBH Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth CHF331.8K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-5.46%
12-Months-Change
Fundamentals
Return on Equity
6.01%
Trailing 12-Months
Asset Growth
2.42%
Trailing 12-Months
Company Description
Zimmer Biomet Holdings
Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products. It operates through the following geographical segments: Americas, Europe Middle East and Africa, and Asia Pacific. The Americas segment consists of the U.S. and includes other North, Central and South American markets. The Europe Middle East and Africa segment includes France, Germany, Italy, Spain, and the United Kingdom. The Asia Pacific segment refers to the key markets such as Japan, China, Australia, New Zealand, Korea, Taiwan, India, Thailand, Singapore, Hong Kong, and Malaysia. The company was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw, IN.
ZBH Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented more positive developments than negative ones: solid top‑line growth (reported and organic), an EPS beat and raised EPS and free cash flow guidance, strong cash generation, accelerating performance from strategic acquisitions (Paragon 28) and clear momentum in technology and robotics (Monogram enrollment complete, ROSA/TMINI adoption). Offsetting items include short‑term disruption from the U.S. salesforce transformation and legacy knee transitions, some international go‑to‑market disruption, a one‑time tariff benefit that partially pulled forward upside, and higher interest expense tied to acquisition debt. On balance the company appears to be executing on its strategic priorities while managing expected transitional headwinds.View all CH:ZBH earnings summariesZBH Net sales Breakdown
40.36% Knees
25.43% Hips
26.12% S.E.T
8.09% Technology & Data, Bone Cement and Surgical

ZBH Stock 12 Month Forecast
Average Price Target
CHF78.44
▲(4.58% Upside)
Technical Analysis
Boston Scientific
―
Edwards Lifesciences
―
Medtronic
―
Smith & Nephew Snats
―
Stryker
―
Options Prices
Currently, No data available
---








